Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.84 USD | -4.33% | -5.00% | -18.46% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.46% | 2.51B | |
+63.69% | 62.59B | |
-1.80% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.69% | 26.21B | |
-21.87% | 19.09B | |
+4.24% | 13.08B | |
+25.64% | 12.26B | |
+28.18% | 12.05B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating